DOCSLIB.ORG

2021 Virtual Nf Conference June 14 - 16, 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2021 Virtual Nf Conference June 14 - 16, 2021 Abstract Book 2021 VIRTUAL NF CONFERENCE JUNE 14 - 16, 2021 KEEPING THE NF COMMUNITY CONNECTED CONTENTS Table of Contents INFORMATION Continuing Medical Education .................................................................................................5 SPEAKER ABSTRACTS Abstracts .............................................................................................................................16 POSTER ABSTRACTS NF1: Basic Science ..............................................................................................................57 NF1: Clinical Science ............................................................................................................87 NF2: Clinical Science ..........................................................................................................140 Schwannomatosis: Basic Science ......................................................................................142 Schwannomatosis: Clinical Science ....................................................................................144 2021 NF Virtual Conference · June 14-16, 2021 | 3 This Activity is Supported in Part by an Independent Education Grant from AstraZeneca 4 | Children’s Tumor Foundation · Ending Neurofibromatosis Through Research 2021 Virtual Neurofibromatosis (NF) Conference June 14-16, 2021 This accredited continuing education (CE) activity is jointly provided by Medical Learning Institute, Inc. and Children’s Tumor Foundation. Target Audience This accredited CE activity is directed towards oncologists, pediatric neuro-oncologists, pediatricians, genetic counselors, nurses/nurse practitioners, and researchers exploring tumor pathways. Educational Objectives After completing this accredited CE activity, the participant should be better able to: Clinical Research 1. Review gaps between theoretical and actual care delivery and how this can be addressed 2. Evaluate unmet needs and guideline-driven medical care for NF patients in European nations including France, England, Spain, Portugal, Norway, Sweden, and Italy, including the possibilities for an international approach to raising the level of care in these countries and eventually across additional nations 3. Outline how to approach planning for the transition from pediatric to adult care settings 4. Summarize barriers to prescribing novel medication for manifestations of neurofibromatosis and schwannomatosis to patients 5. Compare and contrast different approaches to complicated cases of NF in which multiple issues must be address in a coordinated way Basic Research 6. Review the latest scientific breakthroughs related to the biology of NF 7. Describe the major outstanding questions related to the molecular and cellular biology of NF 8. Summarize how basic science relates to the development of NF tumors and other NF-associated conditions Translational Research 9. Show how molecular advances have allowed targeted therapy for NF complications 10. Review how new potential treatments could translate to clinical effect Program Agenda Please see Agenda tab 2021 NF Virtual Conference · June 14-16, 2021 | 5 Physician Continuing Medical Education This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and Children’s Tumor Foundation. Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians. Medical Learning Institute, Inc. (MLI) designates this live activity for a maximum of 16.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Commercial Support Statement This activity is supported by an independent educational grant from AstraZeneca. Physician Assistants PAs may claim a maximum of 16.25 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Nursing Continuing Professional Development Medical Learning Institute, Inc. is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. Successful completion of this nursing continuing professional development activity will be awarded 15.25 contact hour(s). and 10.25 contact hour(s) in the area of pharmacology. Disclosures Disclosure & Conflict of Interest Policy Medical Learning Institute, Inc., is committed to providing high quality accredited continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this accredited CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this accredited CE activity, regardless of the amount or their view of the relevance to the accredited education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the accredited CE activity. Faculty The following have no relevant financial relationship(s) with ineligible companies to disclose for this educational activity. Speaker: Allen, Taryn, PhD National Institutes of Health (NIH), US 6 | Children’s Tumor Foundation · Ending Neurofibromatosis Through Research Speaker: Askenazi, Naomi McGill University/Massachusetts General Hospital, US Speaker: Bouley, Stephanie, PhD Massachusetts General Hospital , US Speaker (Patient): Lilly Ann Brooks Speaker: Buono, Frank, PhD Yale University, US Speaker: Burns, Rebecca, MS MGH Institute of Health Professionals Planner: Castellanos, Elisabeth, PhD IDIBELL, Spain Speaker: Catasus, Nuria Germans Trias i Pujol Research Institute, Barcelona, ESP Speaker: Chinoy, Amish, MBBS Manchester University Hospitals NHS Foundation Trust, Manchester, UK Speaker: Da, Jennifer L.W., BA Massachusetts General Hospital Planner: De Raedt, Thomas, PhD Children’s Hospital of Philadelphia Speaker: Dhaenens, Britt, MD, Erasmus University, Netherlands Speaker (Patient): Alwyn Dias Planner: Dodd, Rebecca, PhD University of Iowa, US 2021 NF Virtual Conference · June 14-16, 2021 | 7 Speaker: Drouyer, Matthieu, PhD Children’s Medical Research Institute, The University of Sydney, Westmead, Australia Speaker: Gross, Andrea, MD National Cancer Institute, National Institutes of Health (NIH) US Planner/Speaker: Gutmann, David, MD, PhD, Washington University, St. Louis, US Speaker: Hardin, Haley University of Central Florida Speaker (Patient): Cole Harrell Speaker: Hou, Yang, PhD University of Kentucky Speaker: Kotch, Chelsea, MD Children’s Hospital of Philadelphia Speaker: Laraba, Liyam, PhD University of Plymouth, UK Planner: Martin, Staci, PhD National Institutes of Health (NIH), US Speaker: Martinelli, Maria, MSc University of Central Florida , US Speaker: Mazuelas, Helena, PhD Germans Trias i Pujol Research Institute, ESP Speaker: Merker, Vanessa, PhD Massachusetts General Hospital Planner: Morrison, Helen, PhD Friedrich Schiller University, Jena, Germany 8 | Children’s Tumor Foundation · Ending Neurofibromatosis Through Research Speaker: Ostrow, Kimberly, PhD Johns Hopkins University, US Speaker: Pacot, Laurence, PhD Student Hopital Cochin, Universite de Paris, France Speaker: Pan, Yuan, PhD Stanford University, US Planner: Papi, Laura, MD, University of Florence, Italy Speaker: Pardej, Sara, MS University of Wisconsin-Milwaukee, US Planner: Pasmant, Eric, PhD, Universite de Paris, France Planner: Payne, Jonathan, PsyD, Murdoch Children’s Hospital, Australia Speaker: Perrino, Melissa, MD Cincinnati Children’s Hospital Medical Center, US Speaker: Pundavela, Jay, PhD Cincinnati Children’s Hospital Medical Center, US Planner: Ruggieri, Martino, MD, PhD University of Catania, Italy Speaker: Rhodes, Steven, MD, PhD, Indiana University School of Medicine, US Speaker (Patient): William Riter Speaker: Rivera Polo, Barbara, PhD, IDIBELL, Spain Speaker: Sablina, Anna, PhD, KU Leuven, Belgium Speaker: 2021 NF Virtual Conference · June 14-16, 2021 | 9 Phadnis, Sheetal, MD, University of Alabama at Birmingham, US Speaker: Silber, Sara Children’s National Hospital, Franklin and Marshall College, US Planner/Speaker: Smith, Miriam, PhD University of Manchester, UK Speaker: Struemph, Kari, PhD University of Kansas School of Medicine, US Speaker: Sundby, R. Taylor, MD National Cancer Institute, National Institutes of Health (NIH), US Planner/Moderator: Trapane, Pamela, MD University of Florida School of Medicine - Jacksonville Planner/Moderator: Ullrich, Nicole, MD, PhD Boston Children’s Hospital, US Speaker: van de Ketterij, Edwin MSc European Research Infrastructure for Translational Research (EATRIS) Speaker: Vasudevan, Harish, MD, PhD University of California San Francisco, US Speaker: Williams, Kyle, PhD University of Minnesota, US Speaker: Xu, Lei, MD, PhD Massachusetts General Hospital, US The following have relevant financial relationship(s) with ineligible companies to disclose for this educational activity. Speaker: 10 | Children’s Tumor Foundation
Load more

Recommended publications
  • Print PDF Opens in a New Window
    CADTH ISSUES IN EMERGING HEALTH TECHNOLOGIES Informing Decisions About New Health Technologies Issue July 173 2018 Monoclonal Antibodies for Osteoarthritis of the Hip or Knee Image courtesy of iStock CADTH ISSUES IN EMERGING HEALTH TECHNOLOGIES 1 Authors: Sirjana Pant, Ke Xin Li, Melissa Severn Cite As: Monoclonal Antibodies for Osteoarthritis of the Hip or Knee. Ottawa: CADTH; 2018. (CADTH issues in emerging health technologies; issue 173). Acknowledgments: CADTH would like to acknowledge the contribution of Dr. Tom Appleton, MD, PhD, FRCPC, Assistant Professor, Rheumatologist; Department of Medicine, Department of Physiology and Pharmacology, The University of Western Ontario; Clinician Scientist, Lawson Health Research Institute; The Rheumatology Centre, St. Joseph’s Health Care London; for his review of the draft version of this bulletin. ISSN: 1488-6324 (online) Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy- makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix
    United States International Trade Commission Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix USITC Publication 4208 December 2010 U.S. International Trade Commission COMMISSIONERS Deanna Tanner Okun, Chairman Irving A. Williamson, Vice Chairman Charlotte R. Lane Daniel R. Pearson Shara L. Aranoff Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix Publication 4208 December 2010 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 15, 2010, set forth at the end of this publication, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the United States International Trade Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement changes to the Pharmaceutical Appendix, effective on January 1, 2011. Table 1 International Nonproprietary Name (INN) products proposed for addition to the Pharmaceutical Appendix to the Harmonized Tariff Schedule INN CAS Number Abagovomab 792921-10-9 Aclidinium Bromide 320345-99-1 Aderbasib 791828-58-5 Adipiplon 840486-93-3 Adoprazine 222551-17-9 Afimoxifene 68392-35-8 Aflibercept 862111-32-8 Agatolimod
    [Show full text]
  • Primate Specific Retrotransposons, Svas, in the Evolution of Networks That Alter Brain Function
    Title: Primate specific retrotransposons, SVAs, in the evolution of networks that alter brain function. Olga Vasieva1*, Sultan Cetiner1, Abigail Savage2, Gerald G. Schumann3, Vivien J Bubb2, John P Quinn2*, 1 Institute of Integrative Biology, University of Liverpool, Liverpool, L69 7ZB, U.K 2 Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, The University of Liverpool, Liverpool L69 3BX, UK 3 Division of Medical Biotechnology, Paul-Ehrlich-Institut, Langen, D-63225 Germany *. Corresponding author Olga Vasieva: Institute of Integrative Biology, Department of Comparative genomics, University of Liverpool, Liverpool, L69 7ZB, [email protected] ; Tel: (+44) 151 795 4456; FAX:(+44) 151 795 4406 John Quinn: Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, The University of Liverpool, Liverpool L69 3BX, UK, [email protected]; Tel: (+44) 151 794 5498. Key words: SVA, trans-mobilisation, behaviour, brain, evolution, psychiatric disorders 1 Abstract The hominid-specific non-LTR retrotransposon termed SINE–VNTR–Alu (SVA) is the youngest of the transposable elements in the human genome. The propagation of the most ancient SVA type A took place about 13.5 Myrs ago, and the youngest SVA types appeared in the human genome after the chimpanzee divergence. Functional enrichment analysis of genes associated with SVA insertions demonstrated their strong link to multiple ontological categories attributed to brain function and the disorders. SVA types that expanded their presence in the human genome at different stages of hominoid life history were also associated with progressively evolving behavioural features that indicated a potential impact of SVA propagation on a cognitive ability of a modern human.
    [Show full text]
  • Genetic and Genomic Analysis of Hyperlipidemia, Obesity and Diabetes Using (C57BL/6J × TALLYHO/Jngj) F2 Mice
    University of Tennessee, Knoxville TRACE: Tennessee Research and Creative Exchange Nutrition Publications and Other Works Nutrition 12-19-2010 Genetic and genomic analysis of hyperlipidemia, obesity and diabetes using (C57BL/6J × TALLYHO/JngJ) F2 mice Taryn P. Stewart Marshall University Hyoung Y. Kim University of Tennessee - Knoxville, [email protected] Arnold M. Saxton University of Tennessee - Knoxville, [email protected] Jung H. Kim Marshall University Follow this and additional works at: https://trace.tennessee.edu/utk_nutrpubs Part of the Animal Sciences Commons, and the Nutrition Commons Recommended Citation BMC Genomics 2010, 11:713 doi:10.1186/1471-2164-11-713 This Article is brought to you for free and open access by the Nutrition at TRACE: Tennessee Research and Creative Exchange. It has been accepted for inclusion in Nutrition Publications and Other Works by an authorized administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact [email protected]. Stewart et al. BMC Genomics 2010, 11:713 http://www.biomedcentral.com/1471-2164/11/713 RESEARCH ARTICLE Open Access Genetic and genomic analysis of hyperlipidemia, obesity and diabetes using (C57BL/6J × TALLYHO/JngJ) F2 mice Taryn P Stewart1, Hyoung Yon Kim2, Arnold M Saxton3, Jung Han Kim1* Abstract Background: Type 2 diabetes (T2D) is the most common form of diabetes in humans and is closely associated with dyslipidemia and obesity that magnifies the mortality and morbidity related to T2D. The genetic contribution to human T2D and related metabolic disorders is evident, and mostly follows polygenic inheritance. The TALLYHO/ JngJ (TH) mice are a polygenic model for T2D characterized by obesity, hyperinsulinemia, impaired glucose uptake and tolerance, hyperlipidemia, and hyperglycemia.
    [Show full text]
  • Revision of Diagnostic Criteria for Neurofibromatosis
    Revision of Diagnostic Criteria for Neurofibromatosis Gareth Evans, MD, St. Mary’s Hospital/University of Manchester, UK Susan Huson, MD, Consultant Geneticist, UK Eric Legius, MD, PhD, University of Leuven, Belgium Ludwine Messiaen, PhD, University of AlaBama, Birmingham, USA Scott Plotkin, MD, PhD, Massachusetts General Hospital, USA Pierre Wolkenstein, MD, PhD, Hôpital Henri-Mondor, France 2019 NF Conference San Francisco, CA September 21, 2019 Revision of the Diagnostic Criteria of the Neurofibromatoses 92 medical specialists 20 countries 5 continents We want your feedback! Send email to: [email protected] Participants in revision process: Leadership team Clinical Epidemiology Health Services Research: Ophthalmology: • Gareth Evans • Nilton Rezende • Vanessa Merker • Robert Avery • Sue Huson • Catherine Cassiman • Eric Legius Clinical Genetics: Internal Medicine: Pathology: • Ludwine Messiaen • Dorothy Halliday • Luiz Oswaldo Carneiro • Karin Cunha • Scott Plotkin • Maurizio Clementi Rodrigues • Anat Stemmer-Rachamimov • Pierre Wolkenstein • Arvid Heiberg • Patrice Pancza • Joanne Ngeow Scientists: Pediatrics: • Shay Ben-Schachar • Miriam Smith • Outside Experts: • Bruce Korf • Marco Giovannini Rianne Oostenbrink • • Monique Anten • Mimi Berman • Eduard Serra Robert Listernick • Jaan Toelen • Betty Schorry • Juha Peltonen Pediatric Hematology and • Arthur Aylsworth • Gareth Evans Oncology: • Meredith Wilson • Ignacio Blanco Molecular Genetics: • Michael Fisher • Helen Hanson • Dusica Babovic-Vuksanovic •Laura Papi • Christopher
    [Show full text]
  • Discovery of Genes by Phylocsf Supplemental
    Supplemental Materials for Discovery of high-confidence human protein-coding genes and exons by whole-genome PhyloCSF helps elucidate 118 GWAS loci Supplemental Methods ....................................................................................................................... 2 Supplemental annotation methods ........................................................................................................... 2 Manual annotation overview ...................................................................................................................................... 2 Summary diagram for the workflow used in this study ................................................................................. 3 Transcriptomics analysis ............................................................................................................................................. 3 Comparative annotation ............................................................................................................................................... 4 Overlap of novel annotations with transposon sequences ........................................................................... 6 Assessing the novelty of annotations ...................................................................................................................... 7 Additional considerations for the annotation of PCCRs in other species ............................................... 7 PhyloCSF and browser tracks ....................................................................................................................
    [Show full text]
  • 2018 Abstract Book
    CONTENTS Table of Contents INFORMATION Continuing Medical Education .................................................................................................5 Guidelines for Speakers ..........................................................................................................6 Guidelines for Poster Presentations .........................................................................................8 SPEAKER ABSTRACTS Abstracts ...............................................................................................................................9 POSTER ABSTRACTS Basic Research (Location – Room 101) ...............................................................................63 Clinical (Location – Room 8) ..............................................................................................141 2018 Joint Global Neurofibromatosis Conference · Paris, France · November 2-6, 2018 | 3 4 | 2018 Joint Global Neurofibromatosis Conference · Paris, France · November 2-6, 2018 EACCME European Accreditation Council for Continuing Medical Education 2018 Joint Global Neurofibromatosis Conference Paris, France, 02/11/2018–06/11/2018 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for a maximum of 27 European CME credits (ECMEC®s). Each medical specialist should claim only those credits that he/she actually spent in the educational activity. The EACCME® is an institution of the European Union of Medical Specialists (UEMS), www.uems.net. Through an agreement between
    [Show full text]
  • Schwannomatosis: Tumors That Affect the Nervous System
    In partnership with Primary Children’s Hospital Schwannomatosis: Tumors that affect the nervous system Schwannomatosis (sh-WAHN-no-muh-TOH-siss) is a genetic What are the signs disorder that causes noncancerous (benign) tumors, of schwannomatosis? called schwannomas, to grow on the peripheral and Signs of schwannomatosis include: spinal nerves. These tumors can cause pain that are • Chronic pain anywhere in the body hard to control. (caused by schwannomas pushing on the nerves) One in 40,000 people worldwide develop • Numbness or tingling schwannomatosis, a rare form of neurofibromatosis (new-roh-FIBE-row-muh-TOH-siss) each year. • Headaches Neurofibromatosis is a group of genetic disorders • Vision changes that affect the nervous system. • Weakness (including facial weakness) What causes schwannomatosis? • Problems with bowel movements Because schwannomatosis is a genetic disorder, your child either: • Trouble urinating • Inherited an abnormal gene from a parent, or Your child may have mild or severe pain, and they • Inherited a gene mutation may not have other symptoms of schwannomatosis until later. This makes it hard to diagnose Many children who have schwannomatosis are the the disorder. first in their family to have symptoms of the disorder. However, these children can then pass How is schwannomatosis diagnosed? schwannomatosis to their own children. Your child’s healthcare provider will look at your child and ask questions about their pain and symptoms. Sometimes the provider may be able to feel a tumor during a physical exam,
    [Show full text]
  • DGCR8 Microprocessor Defect Characterizes Familial Multinodular Goiter with Schwannomatosis
    The Journal of Clinical Investigation CLINICAL MEDICINE DGCR8 microprocessor defect characterizes familial multinodular goiter with schwannomatosis Barbara Rivera,1,2,3 Javad Nadaf,2,3 Somayyeh Fahiminiya,4 Maria Apellaniz-Ruiz,2,3,4,5 Avi Saskin,5,6 Anne-Sophie Chong,2,3 Sahil Sharma,7 Rabea Wagener,8 Timothée Revil,5,9 Vincenzo Condello,10 Zineb Harra,2,3 Nancy Hamel,4 Nelly Sabbaghian,2,3 Karl Muchantef,11,12 Christian Thomas,13 Leanne de Kock,2,3,5 Marie-Noëlle Hébert-Blouin,14 Angelia V. Bassenden,15 Hannah Rabenstein,8 Ozgur Mete,16,17 Ralf Paschke,18,19,20,21,22 Marc P. Pusztaszeri,23 Werner Paulus,13 Albert Berghuis,15 Jiannis Ragoussis,4,9 Yuri E. Nikiforov,10 Reiner Siebert,8 Steffen Albrecht,24 Robert Turcotte,25,26 Martin Hasselblatt,13 Marc R. Fabian,1,2,3,7,15 and William D. Foulkes1,2,3,4,5,6 1Gerald Bronfman Department of Oncology, McGill University, Montreal, Quebec, Canada. 2Lady Davis Institute for Medical Research and 3Segal Cancer Centre, Jewish General Hospital, Montreal, Quebec, Canada. 4Cancer Research Program, McGill University Health Centre, Montreal, Quebec, Canada. 5Department of Human Genetics, McGill University, Montreal, Quebec, Canada. 6Division of Medical Genetics, Department of Medicine, McGill University Health Centre and Jewish General Hospital, Montreal, Quebec, Canada. 7Department of Experimental Medicine, McGill University, Montreal, Quebec, Canada. 8Institute of Human Genetics, University of Ulm and University of Ulm Medical Center, Ulm, Germany. 9Génome Québec Innovation Centre, McGill University, Montreal, Quebec, Canada. 10Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. 11Department of Diagnostic Radiology, McGill University, Montreal, Quebec, Canada.
    [Show full text]
  • February 2021 EPS Pipeline Report
    Pipeline Report February 2021 Pipeline Report February 2021 © 2021 Envolve. All rights reserved. Page 1 This quarterly at-a-glance publication is developed by our Clinical Pharmacy Drug Information team to increase your understanding of the drug pipeline, Table of Contents ensuring you’re equipped with insights to prepare for shifts in pharmacy benefit management. In this issue, you’ll learn more about key themes and notable drugs referenced in the following points. COVID-19 1 > Veklury is currently the only agent that is FDA-approved for the treatment of COVID-19. Three additional therapeutics and two vaccines have been granted Emergency Use Authorization (EUA), and at least three more vaccines are Recent Specialty Drug Approvals1 4 expected to receive an EUA in the relatively near future. > The previous quarter noted the approval of several breakthrough therapies for rare or ultra-rare conditions, which previously had no available FDA-approved Recent Non-Specialty Drug Approvals 9 treatments — Zokinvy for Hutchinson-Gilford progeria syndrome and progeroid laminopathies, Oxlumo for primary hyperoxaluria type 1, and Imcivree for genetically mediated obesity. Upcoming Specialty Products 10 > Other notable approvals include: Lupkynis — the first oral therapy approved for lupus nephritis; Orladeyo — the first oral therapy approved as prophylaxis of hereditary angioedema attacks;Cabenuva – the first long-acting injectable antiretroviral therapy intended as maintenance treatment of HIV; and Breyanzi — Upcoming Non-Specialty Products 18 the
    [Show full text]
  • Antibodies to Watch in 2021 Hélène Kaplona and Janice M
    MABS 2021, VOL. 13, NO. 1, e1860476 (34 pages) https://doi.org/10.1080/19420862.2020.1860476 PERSPECTIVE Antibodies to watch in 2021 Hélène Kaplona and Janice M. Reichert b aInstitut De Recherches Internationales Servier, Translational Medicine Department, Suresnes, France; bThe Antibody Society, Inc., Framingham, MA, USA ABSTRACT ARTICLE HISTORY In this 12th annual installment of the Antibodies to Watch article series, we discuss key events in antibody Received 1 December 2020 therapeutics development that occurred in 2020 and forecast events that might occur in 2021. The Accepted 1 December 2020 coronavirus disease 2019 (COVID-19) pandemic posed an array of challenges and opportunities to the KEYWORDS healthcare system in 2020, and it will continue to do so in 2021. Remarkably, by late November 2020, two Antibody therapeutics; anti-SARS-CoV antibody products, bamlanivimab and the casirivimab and imdevimab cocktail, were cancer; COVID-19; Food and authorized for emergency use by the US Food and Drug Administration (FDA) and the repurposed Drug Administration; antibodies levilimab and itolizumab had been registered for emergency use as treatments for COVID-19 European Medicines Agency; in Russia and India, respectively. Despite the pandemic, 10 antibody therapeutics had been granted the immune-mediated disorders; first approval in the US or EU in 2020, as of November, and 2 more (tanezumab and margetuximab) may Sars-CoV-2 be granted approvals in December 2020.* In addition, prolgolimab and olokizumab had been granted first approvals in Russia and cetuximab saratolacan sodium was first approved in Japan. The number of approvals in 2021 may set a record, as marketing applications for 16 investigational antibody therapeutics are already undergoing regulatory review by either the FDA or the European Medicines Agency.
    [Show full text]
  • Faculty Research, Scholarship, and Creative Activity 2017
    STATE UNIVERSITY OF NEW YORK AT FREDONIA FACULTY RESEARCH, SCHOLARSHIP, AND CREATIVE ACTIVITY 2017 fredonia.edu/academicaffairs STATE UNIVERSITY OF NEW YORK AT FREDONIA FACULTY RESEARCH, SCHOLARSHIP, AND CREATIVE ACTIVITY 2017 TABLE OF CONTENTS A MESSAGE FROM THE PRESIDENT .........................4 A MESSAGE FROM THE PROVOST ...........................5 COLLEGE OF EDUCATION ....................................6 CURRICULUM AND INSTRUCTION ................................... 7 LANGUAGE, LEARNING, AND LEADERSHIP ........................... 8 COLLEGE OF LIBERAL ARTS AND SCIENCES ................ 10 BIOLOGY .............................................................. 11 CHEMISTRY AND BIOCHEMISTRY ................................... 13 COMMUNICATION DISORDERS AND SCIENCES ..................... 14 COMMUNICATION .................................................... 14 COMPUTER AND INFORMATION SCIENCES ......................... 16 ENGLISH .............................................................. 17 HISTORY .............................................................. 18 MATHEMATICAL SCIENCES ........................................... 19 PHILOSOPHY ........................................................ 20 PHYSICS ............................................................... 21 POLITICS AND INTERNATIONAL AFFAIRS ........................... 22 PSYCHOLOGY ....................................................... 23 SOCIOCULTURAL AND JUSTICE SCIENCES ......................... 25 COLLEGE OF VISUAL AND PERFORMING ARTS .............26 MUSIC
    [Show full text]